EG330305 Inhibitors
EG330305 inhibitors are a class of small molecules specifically designed to target and inhibit the function of the EG330305 protein. This protein is a member of a larger family of enzymes that play a crucial role in various biochemical pathways, often involving the regulation of cellular processes such as metabolism, signaling, and structural stability. The inhibitors in this class typically function by binding to active or regulatory sites of EG330305, thereby disrupting its enzymatic activity. Structurally, these inhibitors share certain core chemical motifs that are essential for their high binding affinity and specificity. They often possess a combination of aromatic rings, heterocyclic structures, and functional groups that enhance their interaction with the target protein. Some EG330305 inhibitors are designed to be highly selective, minimizing cross-reactivity with other members of the protein family, which allows for a more focused approach in modulating cellular pathways governed by EG330305.
The design and synthesis of EG330305 inhibitors are based on a detailed understanding of the protein's structure and function. Crystallography and computational modeling have been pivotal in identifying key binding pockets and regions on the protein surface, guiding the rational design of inhibitors. The activity of these inhibitors is usually assessed in vitro using biochemical assays that measure the enzymatic activity of EG330305 in the presence of varying concentrations of the compound. Additionally, their physicochemical properties such as solubility, stability, and binding kinetics are carefully evaluated to ensure optimal performance under experimental conditions. The inhibitors are often fine-tuned through structure-activity relationship (SAR) studies, which help improve their efficacy, specificity, and bioavailability. Such compounds are valuable tools for probing the biological function of EG330305 in cellular models, providing insights into the pathways and mechanisms controlled by this protein and the broader implications for cellular regulation and homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor affecting histone acetylation. Vorinostat inhibits HDACs, indirectly influencing Gm5111 expression by modulating histone acetylation, revealing the epigenetic regulation of Gm5111. The intricate interplay between histone modifications and Gm5111 suggests potential roles in chromatin dynamics. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting the PI3K/Akt pathway. LY294002 inhibits PI3K, indirectly influencing Gm5111 through the PI3K/Akt pathway. The complex signaling network involving PI3K/Akt suggests Gm5111's role in cell survival, growth, and metabolism in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor affecting the MAPK pathway. Trametinib inhibits MEK, indirectly influencing Gm5111 through the MAPK pathway. Gm5111's connection to the MAPK pathway implies a potential role in regulating cellular processes, such as proliferation and differentiation, in response to external signals. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB inhibitor impacting inflammatory signaling. BAY 11-7082 inhibits NF-κB, indirectly influencing Gm5111 through the NF-κB signaling pathway. The connection between Gm5111 and NF-κB suggests a potential role in inflammatory responses and immune regulation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
BET inhibitor affecting gene expression. JQ1 inhibits BET proteins, indirectly influencing Gm5111 by modulating the expression of genes involved in cellular processes. The association of Gm5111 with BET proteins hints at its potential involvement in transcriptional regulation and epigenetic control. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor affecting the PI3K/Akt pathway. Wortmannin inhibits PI3K, indirectly influencing Gm5111 through the PI3K/Akt pathway. Gm5111's association with the PI3K/Akt pathway implies potential roles in cell survival, growth, and metabolic regulation in response to various stimuli. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor impacting the MAPK pathway. SB203580 inhibits p38 MAPK, indirectly influencing Gm5111 through the MAPK pathway. The connection between Gm5111 and p38 MAPK hints at its potential role in mediating cellular responses to stress, inflammation, and growth factors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the MAPK pathway. SP600125 inhibits JNK, indirectly influencing Gm5111 through the MAPK pathway. The association of Gm5111 with the JNK pathway suggests a potential role in regulating cellular responses to stress, inflammation, and growth signals. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $130.00 | 12 | |
p38 MAPK inhibitor impacting the MAPK pathway. BIRB 796 inhibits p38 MAPK, indirectly influencing Gm5111 through the MAPK pathway. Gm5111's link to the p38 MAPK pathway implies potential involvement in cellular responses to stress, inflammation, and growth signals. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
Akt inhibitor affecting the PI3K/Akt pathway. MK-2206 inhibits Akt, indirectly influencing Gm5111 through the PI3K/Akt pathway. Gm5111's connection to the PI3K/Akt pathway suggests potential roles in cell survival, growth, and metabolic regulation in response to various stimuli. | ||||||